Localization! Stago inaugurates new medical device production site

Dedicated to thrombosis and hemostasis diagnosis, more than 70 years to push the new, Stago is once again new debut, the completion of a new medical device production base, the first to truly realize the equipment localization of the blood clotting import brand.

On June 9, a launching ceremony was held for the Stago Medical Device Factory. Kou Xiaoshuang, Deputy Director of Tianjin Port Free Trade Zone Administrative Committee, Philippe Barroux, General Manager of Stago China and Tianjin Stago Medical Devices Co., Cao Lixiang, Secretary of the General Party Branch and Chairman of the Board of Directors of Tianbao Construction Company, Yang Zihong, Executive Vice President of Tianjin Institute of the Sixth Design and Research Institute of Machinery Industry of SINOMACH Group, as well as French law firm Deschamps and Tianjin Development Zone Ono Shipping Co., attended.

Looking to the future, the blueprint for further expansion is about to unfold, gradually fulfilling Stago's long-term strategy to establish its roots in China. In this way, Stago Tianjin will become a production base of the same standard as Stago worldwide, presenting the same level of technology as the headquarter factory in France, with an advanced quality management system to ensure high efficiency and high quality in the production process.

The opening of the new factory will lay the foundation for the continued expansion of Stago into China to meet the needs of the local medical and healthcare industry. At the same time, it will further respond to the direction of the Chinese medical reform, help the implementation of health strategies and the decentralization of quality medical resources, so that the international leading level of expertise to serve the majority of China's clinical laboratories for the ultimate benefit of Chinese patients and people.

DiaSorin's Shanghai Baoshan factory is officially opened

On June 9, the opening ceremony of DiaSorin’s Baoshan factory was held. Mr. Chen Jianzhong, President and Chairman of the Board of Directors of DiaSorin China, presided over the opening ceremony. Mr. Wang Yi, the Chinese shareholder and Vice Chairman of DiaSorin China, Mr. Shi Yunguang, the Chinese shareholder/director and Corporate Affairs Officer of DiaSorin China, Mr. Jens Ewert, the Vice Chairman of European Union Chamber of Commerce in China Shanghai, and Ms. Giada Piccinini, the board member of Italian Chamber of Commerce in China, were invited to attend the event. At the same time, many DiaSorin’s customers, senior experts and industry experts also came to the scene, and the president of Shandong University Institute of Innovative Technology in Laboratory Medicine, Mr. Wang Chuanxin, also expressed his blessing through video, which witnessed another milestone of DiaSorin Group's strategic layout of production localization in China.

The opening of the Shanghai Baoshan site, the newest and most advanced production + R&D center within the DiaSorin Group, clearly demonstrates the attitude and confidence of DiaSorin Group in the Chinese market. For more than three years from the end of 2019 to 2022, DiaSorin China has overcome various difficulties such as the new crown epidemic and struggled against the odds to complete the construction of the Baoshan production base as planned with the full support of Baoshan District Government, Baoshan High-tech Zone Administrative Committee and other governmental functions.